Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares are trading lower on Thursday as investors digest an update on its European patent fight with Merck, while risk appetite is already soft with the S&P 500 down 0.31% and Healthcare sliding 1.82% (the weakest sector today).
Merck & Co., Inc. NYSE: MRK is studying how its experimental personalized cancer vaccine might work across different tumor types, with kidney cancer data expected to help determine whether the approach can extend beyond tumors with a high number of mutations, a company executive said at the Jefferies Healthcare Conference.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Isomorphic Labs, an AI-first drug design and development company, today announced a research collaboration that brings together Isomorphic Labs' AI approach to drug discovery with Merck's rich proprietary data resources and deep discovery experience. The companies will collaborate to discover therapeutic small molecule candidates against an oncology target of strategic importance. Isomorp.
Merck and Co., Inc. (NYSE: MRK - Get Free Report) EVP Richard Deluca sold 58,185 shares of the business's stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the sale, the executive vice president owned 112,955 shares of